MVMomchilo Vuyisich

Momchilo Vuyisich

*This is an algorithmically generated author record based on publicly available information.

Momchilo Vuyisich has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metatranscriptomics-Derived Disease Risk Scores as a Preventive, Diagnostic, and Treatment Support Tool

    by Lan Hu, Michael Bass, Eric Patridge, Matthew Molusky, Grant Antoine, Momchilo Vuyisich, Guruduth Banavar

    Background: Chronic diseases and symptom syndromes often develop after prolonged biological changes that may precede formal diagnosis. RNA-based metatranscriptomics captures active microbial and human gene expression and may provide a functional layer for disease risk evaluation. To address this translational gap, we developed and validated a Disease Risk Score (DRS) framework that integrates metatranscriptome-derived pathway activity scores from stool, saliva, and blood samples, and evaluated its potential clinical utility as an adjunct risk-evaluation tool. Methods: DRS uses disease-specific sets of pathway activity scores derived from stool and saliva microbial functions, stool and saliva microbial taxa, and blood human gene expression. For each disease, ‘not optimal’ pathway scores are aggregated into a normalized cumulative odds ratio, or cOR, using score-level odds ratios, statistical significance, and literature-supported biological relevance derived from a Development Cohort of 22,369 individuals. A cOR ≥ 5 is defined as high risk. Performance is evaluated in an independent Validation Cohort of 15,908 individuals using self-reported diseases as the reference. Disease support requires both significant cOR separation between self-reported and not-reported (Cohen’s d ≥ 0.2) and risk ratio enrichment of self-reported disease among individuals classified as high risk (95% CI of Risk Ratio > 1). Results: Of 20 initially evaluated diseases, 15 meet the prespecified validation criteria on the independent validation cohort: ADHD, anxiety, chronic fatigue syndrome, depression, GERD, hypertension, inflammatory bowel disease, IBS-C, IBS-D, insomnia, MASLD, obesity, obstructive sleep apnea, Sjögren’s syndrome, and type 2 diabetes. Five selected clinical scenarios illustrate how DRS can support clinician-mediated decision making, including IBS subtype reclassification, improved diagnostic acceptance in IBS-D, personalized lifestyle counseling in MASLD and early type 2 diabetes, and diagnostic uncertainty in atypical GERD. Conclusions: DRS is a metatranscriptomics-based risk-stratification framework that aggregates active microbial and human pathway signals into interpretable disease-specific risk estimates across a wide range of disease conditions. Validation against self-reported disease labels in an independent cohort shows significant risk enrichment for each of 15 diseases. DRS is intended as an adjunct to clinical evaluation: a decision support tool in situations where routine care encounters uncertainty, delay, or low patient engagement. Future prospective studies using clinically adjudicated endpoints are needed to assess calibration and clinical outcomes.

  • Open Access

    The Human Gut Microbiome Activity Is Resilient and Stable for up to Six Months: A Large Stool Metatranscriptomic Study

    by Ryan Toma, Lan Hu, Nan Shen, Eric Patridge, Robert Wohlman, Guruduth Banavar, Momchilo Vuyisich

    The human microbiome influences health and disease through diverse biochemical and functional outputs (e.g., enzymes, structural proteins, metabolites, and other cellular components) that affect nearly every aspect of human physiology. Metatranscriptomics (MT), an unbiased RNA sequencing approach, is a high-throughput and high-content method that quantifies both gut microbial taxonomy and active biochemical functions. Because microbial community composition and gene expression are dynamic, understanding temporal variation in the gut metatranscriptome across multiple time scales is essential. Here, we report the temporal dynamics of gut microbiome species and functions using a large cohort (n = 6157) with a clinically validated stool MT test. We quantified microbiome stability from hours to years and assessed taxonomic and functional resilience to major luminal perturbations, such as colonoscopy bowel preparation. Longitudinal analyses of samples collected within the same day, and across days, weeks, months, and years, revealed consistently high stability in both composition and gene expression within a single day and, importantly, across an approximate six-month period. Among individuals reporting stable diets and no antibiotic exposure, taxonomic and functional profiles remained stable for up to three years. Following colonoscopy preparation, our preliminary study of the microbiome demonstrated strong resilience, returning to its pre-procedure state within one week. Overall, these findings demonstrate that the gut microbiome is generally stable over a six-month time frame, with longer-term changes occurring gradually. These findings support the robustness of stool-based MT profiling for species-level and pathway-resolved functional analysis in longitudinal research and health applications.

  • Open Access

    The human gut microbiome activity is resilient and stable for up to six months: a large stool metatranscriptomic study

    by Ryan Toma, Lan Hu, Nan Shen, Eric Patridge, Robert Wohlman, Guruduth Banavar, Momchilo Vuyisich

    The human microbiome influences health and disease through diverse biochemical and functional outputs (e.g. enzymes, structural proteins, metabolites, and other cellular components) that affect nearly every aspect of human physiology. Metatranscriptomics (MT), an unbiased RNA sequencing approach, is a high-throughput and high-content method that quantifies both gut microbial taxonomy and active biochemical functions. Because microbial community composition and gene expression are dynamic, understanding temporal variation in the gut metatranscriptome across multiple time scales is essential. Here, we report the temporal dynamics of gut microbiome species and functions using a large cohort (n=6,157) with a clinically validated stool MT test. We quantified microbiome stability from hours to years and assessed taxonomic and functional resilience to major luminal perturbations, such as colonoscopy bowel preparation. Longitudinal analyses of samples collected within the same day, and across days, weeks, months, and years, revealed consistently high stability in both composition and gene expression within a single day and, importantly, across an approximate six-month period. Among individuals reporting stable diets and no antibiotic exposure, taxonomic and functional profiles remained stable for up to three years. Following colonoscopy preparation, our preliminary study of the microbiome demonstrated strong resilience, returning to its pre-procedure state within one week. Overall, these findings demonstrate that the gut microbiome is generally stable over a six-month time frame, with longer-term changes occurring gradually. These findings support the robustness of stool-based MT profiling for species-level and pathway-resolved functional analysis in longitudinal research and health applications.

  • Open Access

    Fecal Microbiome in Women With Fibromyalgia: Functional Composition and Symptom Correlations

    by Sharon Erdrich, Ingrid C. Gelissen, Ryan Toma, Momchilo Vuyisich, Joanna E. Harnett

    Objective: To describe the composition of the gut microbiota of women living with fibromyalgia, compared with controls, and examine the relationship between fecal microbiota and clinical features of fibromyalgia.Methods: New Zealand women meeting American College of Rheumatology fibromyalgia criteria and age‐matched controls provided fecal samples and completed validated surveys assessing pain, disorders of gut–brain interaction (DGBI), headaches, sleep quality, oral health, cognition, anxiety, depression, diet, and quality of life. Metatranscriptomic analysis identified phyla, genera, and species in fecal samples. Correlation coefficients were calculated for each α‐diversity metric against clinical variables. Welch's t‐test or Wilcoxon rank test was applied for binary clinical variables. Generalized linear models analyzed associations in the fibromyalgia group, adjusting for age, body mass index, and diet. Data processing and analysis used R version 4.2.1, with the Benjamini–Hochberg formula controlling for false discovery rate at ≤0.10 to minimize type 1 error risk.Results: No statistically significant differences were seen in the microbial expression in fecal samples of women with fibromyalgia (n = 104) compared with controls (n = 52). Significant associations among three species from the Bacteroidetes phylum and cognitive impairment were observed. Fusobacteriota was significantly associated with Rome IV(B) DGBI, specifically epigastric pain syndrome. A strong association was observed between oral microbiota in feces and upper gastrointestinal DGBI, indicating both negative and positive correlations in this population.Conclusion: No overall differences in fecal microbial expression were found in women with fibromyalgia. However, Bacteroidetes and Fusobacteriota phyla were significantly associated with cognitive impairment and epigastric pain syndrome, respectively. image


  • Open Access

    Characterisation of the Oral Microbiome in Women With Fibromyalgia: An Observational Case–Control Study

    by Sharon Erdrich, Thilini Jayasinghe, Momchilo Vuyisich, Ryan Toma, Ingrid Gelissen, Joanna E. Harnett

    Background: Fibromyalgia is a complex disorder, associated with a range of symptoms, not least of which is chronic, widespread pain. Although several reports have brought the role of oral health in systemic diseases into recent focus, the oral microbiome in fibromyalgia is unexplored. The aim of this study was to compare oral health and the oral microbiome in women with fibromyalgia with that of age‐matched controls. Methods: This observational case–control study recruited adult non‐smoking, non‐diabetic women meeting American College of Rheumatology (ACR) 2016 fibromyalgia criteria and age‐matched controls living in New Zealand. Metatranscriptomic data from salivary samples were evaluated for differences at phyla, genus and species level, with adjustment for age, BMI and added dietary sugar intake. Results were examined against self‐reported oral health. Results: No differences were seen in richness or diversity of oral species between the fibromyalgia ( n = 106) and control ( n = 52) groups. Women with fibromyalgia had significantly lower scores on measures of oral health, which were associated with subtle shifts in the core oral microbiome. Several oral genera were significantly correlated with oral health scores ( q ≤ 0.05). Higher relative abundance of the periopathogens Prevotella denticola and Solobacterium moorei was apparent in women with fibromyalgia. Conclusion: Significant differences in oral health and the oral microbiome were seen in women with fibromyalgia. This novel discovery presents an intriguing hypothesis that invites deeper investigation into the interaction between oral health and the oral microbiome in this population, and whether these influence the aetiology and/or symptoms of fibromyalgia in women. Significance: This study presents the first evidence of altered oral microbiome in women with fibromyalgia, revealing significant disparities in oral health and the microbiome. The observed overabundance of periopathogens and the underrepresentation of commensals compared to a control group suggest intriguing potential links between the oral microbiome and fibromyalgia symptoms. These findings indicate that enhancing oral health may have broader implications for disease management and lay a robust foundation for further exploration of oral–systemic interactions in fibromyalgia.


  • Open Access

    Preparation of robust synthetic control samples and their use in a metatranscriptomic clinical test

    by Ryan Toma, Lan Hu, Guru Banavar, Momchilo Vuyisich

    Metatranscriptomics (MT) has the potential to revolutionize the field of molecular diagnostics. Due to the complexity of MT diagnostic models, positive and negative control materials for specific disease indications can be difficult to obtain. Controls must often be sourced directly from patients. This introduces logistical burdens, assay variability, and limits high throughput clinical laboratory operations. To overcome this limitation, we developed a method for generating Synthetic Control (SC) samples, which duplicate the nucleic acid signature of complex clinical specimens and produce the desired test outcome. SCs can be easily and cost-effectively produced in large quantities (> 100,000 SCs per amplification cycle), enabling high throughput diagnostic testing. Here, we report the generation of Synthetic Positive Control (SPC) samples. SPCs were validated and implemented in a clinical laboratory. The SPCs produced robust positive signals (average OC risk score of 0.996) and high levels of reproducibility (%CV of 0.29%) in a high throughput automated CLIA laboratory. SCs are a novel and useful method for the generation of high quality controls for MT-based diagnostic tests, and their adoption could herald the widespread use of MT tests in molecular diagnostics.

  • Open Access

    Manhattan Projects for Preventive Medicine

    by Momchilo Vuyisich, Ryan F. Toma, Holiday Goodreau, Emmanuel Hanon, Damon Tanton, Lavinia Alberi Auber, Nikki M. Schultek, Rupy Aujla, Edward J. Zuckerberg, Guruduth Banavar

    In this opinion article, we argue that the requisite scientific knowledge and technological capabilities to elucidate the fundamental causes of chronic diseases—and to develop strategies for their prevention, reversal, and cure—already exist today. However, to implement this vision, a transformative shift in the scientific approach is required ( Figure 1 ). We advocate for a new way to conduct science, inspired by the organizational structure, interdisciplinary synergy, and operational excellence of the Manhattan Project (not its goal of developing a weapon). This model will overcome the current fragmentation of the scientific efforts, which are dispersed across tens of thousands of isolated projects, each with distinct objectives, datasets, methodologies, and analyses. It will also not be distracted and disoriented by the current incentive structure in academic research, which focuses on publications. By adopting the collaborative and goal-oriented framework of the Manhattan Project, humanity can refocus the scientific efforts to effectively confront and consign chronic diseases to the annals of history.


  • Open Access

    Data-Driven Personalized Nutrition Reduces HbA1c in a Prediabetic and Diabetic Population – a Pilot, Randomized, Placebo-Controlled Clinical Trial

    by Momchilo Vuyisich, Grant Antoine, Morvarid Mehrtash, Hilary Keiser, Janelle Connell, Oyetunji Ogundijo, Nan Shen, Cristina Julian, Madhavi Garimella, Guruduth Banavar, et al.

    Type 2 Diabetes (T2D) is a major public health concern. We have previously shown that the biochemical functions of the gut microbiome contribute to the postprandial glucose response and built a machine learned (ML) model that can personalize dietary choices using a stool metatranscriptomic test. We integrated this data-driven personalized nutrition process into the Viome Precision Nutrition Program (VPNP), which includes sample collection kits (capillary blood and stool), an AI/ML nutritional recommendation engine, and an app for digital delivery of dietary recommendations. To test the efficacy of VPNP, we conducted a decentralized, blinded, randomized, placebo-controlled trial in a prediabetic and diabetic adult population in the USA, with HbA1c as the primary endpoint. For this pilot trial, we recruited 27 participants and randomized them into two arms. The placebo arm included sample collection, digital delivery of the USDA dietary recommendations, and physical delivery of supplements filled with inert material. The VPNP (interventional) arm included digital delivery of data-driven and personalized dietary recommendations, and physical delivery of precision supplements. The nutritional intervention lasted ~90 days. The ANCOVA analysis method was employed to control for potential confounders measured at baseline. VPNP intervention (n=12) reduced HbA1c more than the placebo (n=15) in a clinically significant manner (HbA1c difference of 0.42%, p = 0.028). We demonstrate that a precision nutrition program based on stool and blood metatranscriptomic data and AI/ML analyses can significantly reduce HbA1c relative to USDA recommended nutrition in a prediabetic and diabetic population. These results suggest that integrating data-driven precision nutrition into the healthcare system could reduce the burden of T2D.


  • Open Access

    Salivary Transcriptome and Mitochondrial Analysis of Autism Spectrum Disorder Children Compared to Healthy Controls

    by Mark Cannon, Ryan Toma, Sri Ganeshan, Emmery de Jesus Alvarez Varela, Momchilo Vuyisich, Guruduth Banavar

    Autism rates have been reported to be increasing rapidly in industrialized societies. The pathology most often combines neurological symptoms associated with language and social impairments with gastrointestinal symptoms. This study aimed to measure differences in oral metatranscriptome and mitochondrial health between ASD children and neurotypical USA and Colombia (“Blue Zone”) children. In addition, this study aimed to determine whether using prebiotics and probiotics would change the oral microbiome and mitochondrial health of ASD children. Buccal swabs and saliva samples were obtained from 30 autistic individuals (USA) at three intervals: prior to intervention, post-prebiotic, and post-probiotic. In addition, a subject component who were neurotypical, which included individuals from the USA (30) and Colombia (30), had buccal swabbing and salivary sampling performed for metatranscriptomic and mitochondrial comparison. Significant differences were observed in the temporal data, demonstrating shifts that interventions with probiotics and polyols may have precipitated. Particular bacterial strains were significantly more prevalent in the autism group, including a strain that reduced neurotransmitter levels via enzymatic degradation. This supports the hypothesis that the microbiome may influence the occurrence and degree of autism. Verbal skills increased in six of the 30 ASD subjects following xylitol and three more after probiotic supplementation, according to both parental reports and the subjects’ healthcare providers.


  • Open Access

    Manhattan Projects for Preventive Medicine

    by Momchilo Vuyisich, Ryan Toma, Holiday Goodreau, Emmanuel Hanon, Damon Tanton, Lavinia Alberi Auber, Nikki Schultek, Rupy Aujla, Edward Zuckerberg, Guruduth Banavar

    In this opinion article, we argue that the requisite scientific knowledge and technological capabilities to elucidate the fundamental causes of chronic diseases - and to develop strategies for their prevention, reversal, and cure - already exist today. However, to implement this vision, a transformative shift in the scientific approach is required. We advocate for a new way to conduct science, inspired by the organizational structure, interdisciplinary synergy, and operational excellence of the Manhattan Project (not its goal of developing a weapon). This model will overcome the current fragmentation of the scientific efforts, which are dispersed across tens of thousands of isolated projects, each with distinct objectives, datasets, methodologies, and analyses. It will also not be distracted and disoriented by the current incentive structure in academic research, which focuses on publications. By adopting the collaborative and goal-oriented framework of the Manhattan Project, humanity can refocus the scientific efforts to effectively confront and consign chronic diseases to the annals of history.